Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Galapagos in Agreement With Abbott for Rheumatoid Arthritis Drug

Feb. 29 (Bloomberg) -- Galapagos NV said it entered into an agreement with Abbott Laboratories for its rheumatoid arthritis drug and will receive an initial payment of $150 million.

Galapagos would be eligible to receive additional milestone payments from Abbott, potentially amounting to $1 billion, in addition to tiered double-digit royalties on net sales upon commercialization, Galapagos said today in a statement.

Link to Statement:{NSN M056AN3HBS3K <GO>}

Link to Company News:{ABT US <Equity> CN <GO>} Link to Company News:{GLPG BB <Equity> CN <GO>}

To contact the editor responsible for this story: Andrew Clapham at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.